首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 金磚四國(巴西・俄羅斯・印度・中國)的藥品市場
產業/市場分類
製藥 (4452)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (167)
神經疾病 (175)
骨頭疾病治療 (40)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (315)
精神病 (80)
製藥企業 (500)
糖尿病 (157)
癌症 (837)
藥物開發 (1246)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

金磚四國(巴西・俄羅斯・印度・中國)的藥品市場

Pharmaceutical Markets in Brazil, Russia, India and China ( BRIC nations )

出版商 Kalorama Information
出版日期 2008年07月 商品編碼 69415
內容資訊 英文 125 pages
價格
US $ 2500 PDF by E-mail (Single User License)
US $ 3900 Hard Copy
US $ 4300 PDF by E-mail (Single User License) & Hard Copy
US $ 7000 PDF by E-mail (Global Site License)


金磚四國(巴西・俄羅斯・印度・中國)的藥品市場 是由出版商Kalorama Information在2008年07月所出版的。 這份英文市場調查報告書包含125 pages 價格從美金2500起跳。

簡介

本報告書內容包括:BRIC各國藥品市場之國別調查分析、目前的市場規模、2012年之前的成長預測、人口・經濟動向、規範環境、藥品分類別市場動向、主要企業介紹等。內容綱要摘記如下:

第1章 實施概要

  • 概要
  • 調查範圍・調查方法
  • 市場規模・市場成長率
  • 主要課題・市場影響因素
  • 主要競爭企業

第2章 介紹

  • 概要
  • 智慧財產權・強制實施權
  • 生物學名藥
  • 新興國家中與DTC廣告相關的倫理課題
  • 全球健康動向
  • 全球經濟動向
  • 消費能力動向

第3章 印度藥品市場

  • 概要・摘要
  • 規範環境
  • 經濟成長
  • 醫療動向
  • 人口統計
  • 主要產品區隔・市場指標
  • 市場分析

第4章 中國藥品市場

  • 概要・摘要
  • 人口統計
  • 主要產品區隔・市場指標
  • 市場分析

第5章 俄羅斯藥品市場

  • 概要・摘要
  • 規範環境
  • 經濟成長
  • 醫療動向
  • 醫療專家
  • 人口統計
  • 主要產品區隔・市場指標
  • 市場分析
  • 產品區隔別市場分析
  • 競爭預測・通路

第6章 巴西藥品市場

  • 概要・摘要
  • 規範環境
  • 經濟成長
  • 醫療動向
  • 醫療專家
  • 人口統計
  • 主要產品區隔・市場指標
  • 市場分析
  • 產品區隔別市場分析
  • 競爭預測・通路

第7章 市場總結

  • 概要
  • 國別市場

第8章 全球領先企業

  • 概要
  • AstraZeneca
  • GlaxoSmithKline
  • Novartis AG
  • Pfizer, Inc.
  • Roche
  • Sanofi-Aventis

附錄

圖表

目錄

Abstract

Pharmaceutical markets in Brazil, Russia, India and China rank among the top twenty markets in the world with the potential to move up in ranking rather quickly. (China's pharmaceutical market, for instance, is expected to show double-digit growth over the next five years.) Developing regions and petro-rich nations will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market.

Kalorama's “Pharmaceutical Markets in Brazil, Russia, India and China (BRIC nations)” takes a solid look at opportunities available for pharmaceutical companies in these emerging markets, including the following information:

  • Competitive Activity
  • Current Market Size
  • Forecast to 2012
  • Population, Economy and Demographics
  • Health Indicators for each Country
  • Market Trends
  • Company Profiles

What economic and demographic factors are driving companies to this market? Who are the major players having success in this area? What should companies know about each country's healthcare system in order to plan their strategy. For each country, this report answers these questions and analyzes markets a look at the following specific segments

  • Cardiovascular Drugs
  • Gastrointestinal Drugs
  • Infection control Drugs
  • Neurotherapeutics/CNS Drugs
  • Oncology Drugs
  • Respiratory Drugs
  • Others

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study, Kalorama Information conducted interviews with more than 80 key industry officials, consultants, health care providers, and government personnel.

These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Overview
  • Scope and Methodology
  • Size and Growth of the Market
  • Key Issues and Trends Affecting the Market
  • Leading Competitors

CHAPTER TWO: INTRODUCTION

  • Overview
  • Intellectual Property Rights and Compulsory Licensing
  • Biosimilar Production
  • Ethical Issues Regarding DTC Advertising in Developing Regions
  • World Health
    • Tobacco Use
    • Obesity
  • World Economic Trends
  • Purchasing Power Trends

CHAPTER THREE: PHARMACEUTICAL MARKETS IN INDIA

  • Overview and Summary
  • Regulatory Environment
  • Economic Development
  • Healthcare Trends in India
    • Healthcare Professionals
  • Demographics
    • Birth Rates
    • Life Expectancy
    • Mortality
    • Leading Causes of Death
  • Key Product Segments and Market Indicators
    • Cardiovascular Drugs
    • Gastrointestinal Drugs
    • Infection Control Drugs
    • Neurotherapuetics and Central Nervous System Drugs
    • Oncology Drugs
    • Respiratory Drugs
    • Other Drugs
  • Market Analysis
    • Product Segment Market Analysis
    • Competitive Outlook and Distribution

CHAPTER FOUR: PHARMACEUTICAL MARKETS IN CHINA

  • Overview and Summary
    • Regulatory Environment
    • Economic Development
    • Healthcare Trends in China
    • Healthcare Professionals
  • Demographics
    • Birth Rates
    • Life Expectancy
    • Mortality
    • Leading Causes of Death
  • Key Product Segments and Market Indicators
    • Cardiovascular Drugs
    • Gastrointestinal Drugs
    • Infection Control Drugs
    • Neurotherapuetics and Central Nervous System Drugs
    • Oncology Drugs
    • Respiratory Drugs
    • Other Drugs
  • Market Analysis
    • Product Segment Market Analysis
    • Competitor Outlook and Distribution

CHAPTER FIVE: PHARMACEUTICAL MARKETS IN RUSSIA

  • Overview and Summary
  • Regulatory Environment
  • Economic Development
  • Healthcare Trends in Russia
  • Healthcare Professionals
  • Demographics
    • Birth Rates
    • Life Expectancy
    • Mortality
    • Leading Causes of Death
  • Key Product Segments and Market Indicators
    • Cardiovascular Drugs
    • Gastrointestinal Drugs
    • Infection Control Drugs
    • Neurotherapuetics and Central Nervous System Drugs
    • Oncology Drugs
    • Respiratory Drugs
    • Other Drugs
  • Market Analysis
  • Product Segment Market Analysis
  • Competitive Outlook and Distribution

CHAPTER SIX: PHARMACEUTICAL MARKETS IN BRAZIL

  • Overview and Summary
  • Regulatory Environment
  • Economic Development
  • Healthcare Trends in Brazil
  • Healthcare Professionals
  • Demographics
    • Birth Rates
    • Life Expectancy
    • Mortality
    • Leading Causes of Death
  • Key Product Segments and Market Indicators
    • Cardiovascular Drugs
    • Gastrointestinal Drugs
    • Infection Control Drugs
    • Neurotherapuetics and Central Nervous System Drugs
    • Oncology Drugs
    • Respiratory Drugs
    • Other Drugs
  • Market Analysis
  • Product Segment Market Analysis
  • Competitive Outlook and Distribution

CHAPTER SEVEN: MARKET SUMMARY

  • Overview
  • Markets by Country

CHAPTER EIGHT: GLOBAL LEADERS

  • Overview
  • AstraZeneca
  • GlaxoSmithKline
  • Novartis AG
  • Pfizer, Inc.
  • Roche
  • Sanofi-Aventis

APPENDIX: LIST OF MAJOR COMPANIES LIST OF EXHIBITS

FIGURES & TABLES:

CHAPTER ONE: EXECUTIVE SUMMARY

  • Figure 1-1: BRIC Market Analysis: 2005-2012

CHAPTER TWO: INTRODUCTION

  • Table 2-1: Percent of Smokers by Country, Adult Population 15+
  • Table 2-2: Percent of Population that is Obese*, Estimated 2005
  • Table 2-3: Total Healthcare Expenditures as a Percent of GDP by Country 2004 and 2006
  • Figure 2-1: Total Healthcare Expenditures as a Percent of GDP by Country 2004 and 2006
  • Table 2-4: Gross National Income Comparison by Country 2000-2005
  • Figure 2-2: Gross National Income Growth by Country 2000-2005

CHAPTER THREE: PHARMACEUTICAL MARKETS IN INDIA

  • Table 3-1: India Pharmaceutical Market as a Percentage of World Market, 2007 and 2012
  • Figure 3-1: India Pharmaceutical Market as a Percentage of World Market, 2007 and 2012
  • Table 3-2: India' s Economic Profile
  • Table 3-3: Gross National Income Per Capita and Growth Comparison for 2005 and 2006
  • Table 3-4: Healthcare Professionals in India by Type, Estimated 2004 and 2007
  • Figure 3-2; Healthcare Professionals in India by Type, Estimated 2004 and 2007
  • Table 3-5: India - Midyear Population, by Age and Sex, 2007 and 2012
  • Figure 3-3: India - Midyear Population, by Age, 2007 and 2012
  • Table 3-6: India Fertility Rates and Births Estimated 2005, 2007; Projected 2008, 2025
  • Figure 3-4: India Fertility Rates and Births, Estimated 2005, 2007; Projected 2008, 2025
  • Table 3-7: India Life Expectancy at Birth, 1980, 1990, 2000, 2004, 2005, 2006, 2007; Projections, 2008 through 2012, and 2025
  • Figure 3-5: India Life Expectancy at Birth by Sex, 1980, 1990, 2000, Projections 2025
  • Table 3-8: India Mortality Rates and Numbers (Estimated 2005, 2007; Projected 2008, 2025)
  • Figure 3-6: India Mortality Rates and Numbers (Estimated 2005, 2007; Projected 2008, 2025)
  • Table 3-9: India Leading Causes of Death, Estimated 2007
  • Figure 3-7: India Leading Causes of Death, Estimated 2007
  • Table 3-10: HIV Indicators, India
  • Figure 3-8: HIV Indicators, India
  • Table 3-11: Tuberculosis Surveillance and Epidemiology, India
  • Figure 3-9: Tuberculosis Surveillance and Epidemiology, India
  • Table 3-12: India Malaria Data, 1990-2003
  • Figure 3-10: India Malaria Data, 1990-2003
  • Table 3-13: Cancer Surveillance and Epidemiology, India
  • Table 3-14: Estimated Cancer Incidence in India by Most Common Types of Cancer, Compared to World
  • Figure 3-12: Estimated Cancer Incidence in India by Most Common Types of Cancer, Compared to World, 2007
  • Table 3-15: India Pharmaceutical Market Analysis, 2005-2007
  • Table 3-16: Forecasted India Pharmaceutical Market Analysis: 2008-2012
  • Figure 3-13: India Pharmaceutical Market Analysis: 2005-2012
  • Table 3-17: India Pharmaceutical Market Analysis and Forecast by Product Segment, 2007 and 2012
  • Figure 3-14: India Pharmaceutical Market Analysis by Product Segment, 2007
  • Figure 3-15: India Pharmaceutical Market Forecast by Product Segment, 2012
  • Table 3-18: Estimated Sales of Pharmaceuticals in India by Local and Foreign Suppliers, 2007
  • Figure 3-16: Estimated Sales of Pharmaceuticals in India by Local and Foreign Suppliers, 2007

CHAPTER FOUR: PHARMACEUTICAL MARKETS IN CHINA

  • Table 4-1: China Pharmaceutical Market as a Percentage of World Market, 2007 and 2012
  • Figure 4-1: China Pharmaceutical Market as a Percentage of World Market, 2007 and 2012
  • Table 4-2: Chinese and U.S. Drug Review Timeline
  • Table 4-3: China' s Economic Profile
  • Table 4-4: Gross National Income Per Capita and Growth Comparison for 2005 and 2006
  • Table 4-5: Healthcare Professionals in China by Type, Estimated 2004 and 2007
  • Figure 4-2: Healthcare Professionals in China by Type, Estimated 2004
  • Table 4-6: China - Midyear Population, by Age and Sex, 2007 and 2012
  • Figure 4-3: China - Midyear Population, by Age, 2007 and 2012
  • Table 4-7: China Fertility Rates and Births (Estimated 2005, 2007; Projected 2008, 2025)
  • Figure 4-4: China Fertility Rates and Births (Estimated 2005, 2007; Projected 2008, 2025)
  • Table 4-8: China Life Expectancy at Birth, 1980, 1990, 2000, 2004, 2005, 2006, 2007; Projections, 2008 through 2012, and 2025
  • Figure 4-5: China Life Expectancy at Birth by Sex, 1980, 1990, 2000, Projections 2025
  • Table 4-9: China Mortality Rates and Numbers (Estimated 2005, 2007; Projected 2008, 2025)
  • Figure 4-6: China Mortality Rates and Numbers (Estimated 2005, 2007; Projected 2008, 2025)
  • Table 4-10: China Leading Causes of Death, Estimated 2007
  • Figure 4-7: China Leading Causes of Death, Estimated 2007
  • Table 4-11: HIV Indicators, China
  • Figure 4-8: HIV Indicators, China
  • Table 4-12: Tuberculosis Surveillance and Epidemiology, China
  • Figure 4-9: Tuberculosis Surveillance and Epidemiology, China
  • Table 4-13: China Malaria Data, 1990-2003
  • Figure 4-10: China Malaria Data, 1990-2003
  • Table 4-14: Cancer Surveillance and Epidemiology, China
  • Table 4-15: Estimated Cancer Incidence in China by Most Common Types of Cancer, Compared to World, 2007
  • Figure 4-11: Estimated Cancer Incidence in China by Most Common Types of Cancer, Compared to World, 2007
  • Table 4-16: China Pharmaceutical Market Analysis, 2005-2007
  • Table 4-17: Forecasted China Pharmaceutical Market Analysis: 2008-2012
  • Figure 4-12: China Pharmaceutical Market Analysis: 2005-2012
  • Table 4-18: China Pharmaceutical Market Analysis and Forecast by Product Segment, 2007 and 2012
  • Figure 4-13: China Pharmaceutical Market Analysis by Product Segment, 2007
  • Figure 4-14: China Pharmaceutical Market Forecast by Product Segment, 2012
  • Table 4-19: Estimated Sales of Pharmaceuticals in China by Local and Foreign Suppliers, 2007
  • Figure 4-15: Estimated Sales of Pharmaceuticals in China by Local and Foreign Suppliers, 2007

CHAPTER FIVE: PHARMACEUTICAL MARKETS IN RUSSIA

  • Table 5-1: Russia Pharmaceutical Market as a Percentage of World Market, 2007 and 2012
  • Figure 5-1: Russia Pharmaceutical Market as a Percentage of World Market, 2007 and 2012
  • Table 5-2: Russia' s Economic Profile
  • Table 5-3: Gross National Income Per Capita and Growth Comparison for 2005 and 2006
  • Table 5-4: Healthcare Professionals in Russia by Type, Estimated 2004 and 2007
  • Figure 5-2: Healthcare Professionals in Russia by Type, Estimated 2004 and 2007
  • Table 5-5: Russia - Midyear Population, by Age and Sex, 2007 and 2012
  • Figure 5-3: Russia - Midyear Population, by Age 2007 and 2012
  • Table 5-6: Russia Fertility Rates and Births (Estimated 2005, 2007; Projected 2008, 2025)
  • Figure 5-4: Russia Fertility Rates and Births (Estimated 2005, 2007; Projected 2008- 2025)
  • Table 5-7: Russia Life Expectancy at Birth, 2005, 2006, 2007; (Projections, 2008 through 2012, and 2025)
  • Figure 5-5: Russia Life Expectancy at Birth by Sex, 2005; Projections 2010 and 2025
  • Table 5-8: Russia Mortality Rates and Numbers (Estimated 2005, 2007; Projected 2008, 2025)
  • Figure 5-6: Russia Mortality Rates and Numbers Estimated 2005, 2007; Projected 2008, 2025
  • Table 5-9: Russia Leading Causes of Death, Estimated 2007
  • Figure 5-7: Russia Leading Causes of Death, Estimated 2007
  • Table 5-10: HIV Indicators, Russia
  • Figure 5-8: HIV Indicators, Russia
  • Table 5-11: Tuberculosis Surveillance and Epidemiology, Russia
  • Figure 5-9: Tuberculosis Surveillance and Epidemiology, Russia
  • Table 5-12: Cancer Surveillance and Epidemiology, Russia
  • Table 5-13: Estimated Cancer Incidence in Russia by Most Common Types of Cancer, Compared to World, 2007
  • Figure 5-10: Estimated Cancer Incidence in Russia by Most Common Types of Cancer, Compared to World, 2007
  • Table 5-14: Russia Pharmaceutical Market Analysis, 2005-2007
  • Table 5-15: Forecasted Russia Pharmaceutical Market Analysis: 2008-2012
  • Figure 5-11: Russia Pharmaceutical Market Analysis: 2005-2012
  • Table 5-16: Russia Pharmaceutical Market Analysis and Forecast by Product Segment, 2007 and 2012
  • Figure 5-12: Russia Pharmaceutical Market Analysis by Product Segment, 2007
  • Figure 5-13: Russia Pharmaceutical Market Forecast by Product Segment, 2012
  • Table 5-17: Estimated Sales of Pharmaceuticals in Russia by Local and Foreign Suppliers, 2007
  • Figure 5-14: Estimated Sales of Pharmaceuticals in Russia by Local and Foreign Suppliers, 2007

CHAPTER SIX: PHARMACEUTICAL MARKETS IN BRAZIL

  • Table 6-1: Brazil Pharmaceutical Market as a Percentage of World Market, 2007 and 2012
  • Figure 6-1: Brazil Pharmaceutical Market as a Percentage of World Market, 2007 and 2012
  • Table 6-2: Brazil' s Economic Profile
  • Table 6-3: Gross National Income Per Capita and Growth Comparison for 2005 and 2006
  • Table 6-4: Healthcare Professionals in Brazil by Type, Estimated 2004 and 2007
  • Figure 6-2: Healthcare Professionals in Brazil by Type, Estimated 2004 and 2007
  • Table 6-5: Brazil - Midyear Population, by Age and Sex, 2007 and 2012
  • Figure 5-3: Brazil - Midyear Population, by Age and Sex, 2007 and 2012
  • Table 6-6: Brazil Fertility Rates and Births
  • Figure 6-4: Brazil Fertility Rates and Births
  • Table 6-7: Brazil Life Expectancy at Birth, 2000, 2005, 2006, 2007; Projections, 2008 through 2012, and 2025
  • Figure 6-5: Brazil Life Expectancy at Birth by Sex, 2000, 2005; Projections 2010, 2025
  • Table 6-8: Brazil Mortality Rates and Numbers
  • Figure 6-6: Brazil Mortality Rates and Numbers
  • Table 6-9: Brazil Leading Causes of Death, Estimated 2007
  • Figure 6-7: Brazil Leading Causes of Death, Estimated 2007
  • Table 6-10: Tuberculosis Surveillance and Epidemiology, Brazil
  • Figure 6-8: Tuberculosis Surveillance and Epidemiology, Brazil
  • Table 6-11: HIV Indicators, Brazil
  • Figure 6-9: HIV Indicators, Brazil
  • Table 6-12: Brazil Malaria Data, 1990-2003
  • Figure 6-10: Brazil Malaria Data, 1990-2003
  • Table 6-13: Cancer Surveillance and Epidemiology, Brazil
  • Table 6-14: Estimated Cancer Incidence in Brazil by Most Common Types of Cancer, Compared to World
  • Figure 6-11: Estimated Cancer Incidence in Brazil by Most Common Types of Cancer, Compared to World, 2007
  • Table 6-15: Brazil Pharmaceutical Market Analysis, 2005-2007
  • Table 6-16: Forecasted Brazil Pharmaceutical Market Analysis: 2008-2012
  • Figure 6-12: Brazil Pharmaceutical Market Analysis: 2005-2012
  • Table 6-17: Brazil Pharmaceutical Market Analysis and Forecast by Product Segment, 2007 and 2012
  • Figure 6-13: Brazil Pharmaceutical Market Analysis by Product Segment, 2007
  • Figure 6-14: Brazil Pharmaceutical Market Forecast by Product Segment, 2012
  • Table 6-18: Estimated Sales of Pharmaceuticals in Brazil by Local and Foreign Suppliers, 2007
  • Figure 6-15: Estimated Sales of Pharmaceuticals in Brazil by Local and Foreign Suppliers, 2007

CHAPTER SEVEN: MARKET SUMMARY

  • Table 7-1: BRIC Market Analysis, 2005-2007
  • Table 7-2: Forecasted BRIC Market Analysis: 2008-2012
  • Figure 7-1: BRIC Market Analysis: 2005-2012
  • Table 7-3: World Pharmaceutical Markets by Country/Region, 2007
  • Figure 7-2: World Pharmaceutical Markets by Country/Region, 2007
Back to Top